Crizotinib, the first ALK inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2011, targets ALK and ROS1 to treat metastatic NSCLC and ALK-positive myofibroblastic tumors [55,56]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.